Portal de Periódicos da CAPES

Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)

2006; Q16635223; Volume: 134; Issue: 3 Linguagem: Inglês

10.4067/s0034-98872006000300009

0717-6163

María Del Pilar Valdés A., Francisca Schroeder H, Vicky Roizen G, Juan Honeyman M, Leonardo Sánchez M,

Dermatology and Skin Diseases

Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade ® )Background: Psoriasis has a moderate or severe course in 25% of patients, requiring systemic therapy that is not always successful.Infliximab is a human-murine monoclonal anti tumor necrosis alpha (TNF-α) antibody.This mediator has a role in the pathogenesis of psoriasis.Aim: To evaluate the use of infliximab in psoriatic patients resistant to conventional therapies.Material and Methods: An open prospective study including eight patients with extensive plaque or erythrodermic psoriasis.They were treated with infliximab 5 mg/kg/dose on weeks 0,2 and 6.Patients were evaluated every 2 weeks for a median lapse of 50.1 weeks.Physical examination, PASI scores (Psoriasis Area Severity Index) and a photographic control, were done in each visit.Results: All the patients responded in the first 10 weeks of follow-up.The mean reduction in PASI score was 86.6%.Six patients received fourth infusion of infliximab at 37.3 weeks, on average.The most common adverse events were pruritus and headache.Conclusions: This group of patients with extensive plaque or erythrodermic psoriasis resistant to conventional therapies, had a good response to infliximab (Rev Méd Chile 2006; 134: 326-31).